OmniCorder Technologies CEO to Speak at Life Sciences and Healthcare Services Summit
Thursday May 6, 9:26 am ET
EAST SETAUKET, N.Y.--(BUSINESS WIRE)--May 6, 2004--OmniCorder Technologies, Inc. (OTCBB Symbol: OMCT - News) today announced that Mark A. Fauci, OmniCorder Technologies' CEO and President, will speak at Life Sciences & Healthcare Services Summit 2004: Creating Financing & Strategy Opportunities sponsored by Greenberg Traurig, LLP on May 6, 2004 in New York City. Mr. Fauci will participate in a discussion of Strategic Opportunities for Life Sciences Companies where he will be joined by a panel of industry experts including analysts, institutional investors, investment bankers, and venture capitalists. The panel, moderated by Al Jacob, Patent Chair for Greenberg Traurig, LLP, will examine current industry trends in the sector as well as the special combination of financing, technology, intellectual property management, regulatory savvy and executive leadership that ensures a company's success into the future.
Commenting on his upcoming presentation, Mr. Fauci said, "I look forward to joining this panel of industry experts and hope that by sharing my experience with OmniCorder Technologies, we can offer the audience new ideas and opportunities for navigating the channels of the life sciences industry."
About The BioScanIR® System:
The Company's BioScanIR® System, which is available commercially in the U.S. and Europe, detects diseases that affect changes in blood perfusion by detecting minute changes in the pattern of infrared photon emissions over time. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the Department of Defense's Ballistic Missile Defense Initiative. The Company owns an exclusive, worldwide license to use the technology for biomedical applications. OmniCorder believes that the BioScanIR® System will improve disease detection and disease management capabilities in many vascular and cancer medical applications. Both cancer and vascular disease are associated with abnormal blood flow in tissues and organs.
About OmniCorder Technologies, Inc.:
OmniCorder Technologies Inc., headquartered in East Setauket, New York, is a leading developer of medical imaging applications using advanced infrared focal plane arrays. OmniCorder provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications.
OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting military and aerospace technology for biomedical applications.
The Company announced a $7.8 million funding which coincided with the reverse acquisition of a publicly traded company in December 2003.
About Greenberg Traurig LLP
Greenberg Traurig LLP is among a select group of international law firms with more than 1,000 attorneys. In the United States, the firm is ranked No. 12 as reported in The National Law Journal's listing of the country's largest law firms. Globally, the firm's more than 1,100 lawyers and governmental professionals in 24 offices strive to bring experience and creativity into every client relationship - whether with an emerging company or a Fortune 500 corporation. For additional information about Greenberg Traurig, visit the firm's Web site at www.gtlaw.com.
Greenberg Traurig has offices in the United States and Europe: Albany, N.Y.; Amsterdam, The Netherlands; Atlanta, Ga.; Boca Raton, Fla.; Boston, Mass.; Chicago, Ill.; Dallas, Texas; Denver, Colo.; Fort Lauderdale, Fla.; Los Angeles, Calif.; Miami, Fla.; Morristown, N.J.; New York, N.Y.; Orange County, Calif.; Orlando, Fla.; Philadelphia, Pa.; Phoenix, Ariz.; Silicon Valley, Calif.; Tallahassee, Fla.; Tysons Corner, Va.; Washington, D.C.; West Palm Beach, Fla.; Wilmington, Del.; and Zurich, Switzerland.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact:
CCRI Corporation
Malcolm McGuire, 800-828-0406
E-mail: mmcguire17@cox.net
or
OmniCorder Technologies, Inc.
Anne Marie Fields, 212-292-5710
Source: OmniCorder Technologies, Inc. |
